Pioglitazone (Thiazolidinediones) 💊

✅ Pioglitazone has a low hypoglycaemia risk when used alone. Hypos are mainly a concern when it is combined with insulin or a sulfonylurea. It is often used as 2nd or 3rd-line therapy in type 2 diabetes where appropriate, especially when insulin resistance is prominent.

ℹ️ About

• 💊 Pioglitazone is an oral glucose-lowering drug used in type 2 diabetes mellitus.
• 📚 Always verify dosing, contraindications, cautions and monitoring in the BNF - Pioglitazone.
• ⏳ Benefits may take several weeks, so review response over time rather than expecting an immediate HbA1c change.
• ⚠️ Its main limitations are weight gain, oedema, heart failure risk, fracture risk and possible bladder cancer risk.

🧬 Mode of Action

• 🧪 Pioglitazone is a thiazolidinedione - TZD or “glitazone”.
• 🔑 It activates PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism.
• 🧈 It improves insulin sensitivity in adipose tissue, liver and skeletal muscle.
• 🍬 It increases peripheral glucose uptake and reduces hepatic glucose output.
• 💧 It can cause fluid retention, which is why heart failure is a major caution/contraindication.

🎯 Indications

• ✅ Type 2 diabetes when glycaemic targets are not met with lifestyle and other glucose-lowering medicines.
• ✅ May be used with metformin, or as part of dual/triple oral therapy depending on patient factors.
• ✅ May be considered where insulin resistance is prominent and oedema/weight gain risk is acceptable.
• ✅ May help delay or avoid insulin in selected patients.
• ⚠️ Choice should consider cardiovascular risk, weight, renal function, frailty, heart failure risk and patient preference.

💊 Dose

• 💊 Usual starting dose: 15–30 mg once daily.
• ⬆️ May be increased according to response and tolerability up to 45 mg once daily.
• 👵 Older or frail patients: start low, titrate cautiously and monitor for oedema, falls and fractures.
• 📆 Review at 3–6 months: stop if there is inadequate glycaemic response.
• 🍽️ Can usually be taken with or without food.

🔁 Interactions

• 📚 Check the BNF for a full interaction list.
• ⬆️ CYP2C8 inhibitors, such as gemfibrozil, may increase pioglitazone levels.
• ⬇️ CYP inducers, such as rifampicin, may reduce the glucose-lowering effect.
• ⚠️ If used with insulin or a sulfonylurea, consider reducing those agents to reduce hypoglycaemia risk.
• 💧 Combination with insulin may increase the risk of oedema and heart failure.

🔎 Monitoring

• 🧫 LFTs: Check before starting; repeat if symptoms or local policy indicate.
• 💧 Fluid status: Monitor for oedema, rapid weight gain, ankle swelling and new/worsening breathlessness.
• ⚖️ Weight: Weight gain is common and may reflect fat gain or fluid retention.
• 🦴 Fracture risk: Use caution in older adults and post-menopausal women.
• 👁️ Vision: Ask about blurred vision or visual change due to rare macular oedema.
• 🩸 Urinary symptoms: Ask about haematuria or bladder symptoms where clinically relevant.
• 🍬 HbA1c: Review response after an appropriate trial, usually around 3–6 months.

⛔ Contraindications / Avoid

• 🚫 Heart failure or history of heart failure.
• 🚫 Significant fluid overload or unexplained oedema.
• 🚫 Active bladder cancer or previous bladder cancer.
• 🚫 Uninvestigated macroscopic haematuria.
• 🚫 Hepatic impairment or active liver disease - confirm details in BNF/local guidance.
• ⚠️ Use caution in people at high risk of fractures.

⚠️ Adverse Effects

• ⚖️ Weight gain
• 💧 Oedema / fluid retention
• 🫁 New or worsening heart failure
• 🦴 Increased fracture risk, especially in women and older adults
• 👁️ Visual disturbance or rare macular oedema
• 🩸 Anaemia
• 🤧 Upper respiratory tract infections or other infections
• 🚽 Possible small increased risk of bladder cancer

🚩 Stop / Seek Advice If

• 🫁 New breathlessness, orthopnoea or signs of heart failure develop.
• 💧 Rapid weight gain or significant oedema occurs.
• 🧫 ALT becomes significantly raised or liver disease is suspected.
• 🚽 Macroscopic haematuria develops.
• 👁️ New visual disturbance occurs.
• ❌ HbA1c response is inadequate after 3–6 months.

🧠 Exam Pearls

• 💡 Pioglitazone improves insulin sensitivity; it does not directly stimulate insulin release.
• 💡 Low hypo risk alone, but hypos can occur with insulin or sulfonylureas.
• 💡 Avoid in heart failure because of fluid retention.
• 💡 Think weight gain, oedema, fractures and bladder cancer caution.
• 💡 Review at 3–6 months and stop if ineffective.

📚 References

• BNF - Pioglitazone
• NICE CKS - Pioglitazone prescribing information
• MHRA - Pioglitazone: risk of bladder cancer